Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is in good health (any underlying chronic illness must be documented to be in stable condition)~* Has documented proof of receipt of 23-valent pneumococcal polysaccharide vaccine ≥1 year prior to study entry~* Is a male or postmenopausal female~Exclusion Criteria:~* Has received prior administration of any pneumococcal vaccine other than 23-valent pneumococcal polysaccharide vaccine~* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease~* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine~* Is known or suspected impairment of immune function~* Has received systemic corticosteroids for \>=14 consecutive days and has not completed treatment \<=30 days prior to study entry, or received systemic corticosteroids exceeding physiologic replacement doses within 14 days prior to study vaccination~* Has a coagulation disorder contraindicating intramuscular vaccination~* Receives immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease~* Has received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion~* Has participated in another clinical study of an investigational product within 2 months before the beginning of or any time during the duration of the current clinical study~* Is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).